Company Aggregate Debt: Trinity Biotech PLC (TRIB)

The stability of Trinity Biotech plc (TRIB) is confirmed by sales of CGM monitors and HIV tests, as evidenced by the changes in debt load displayed on GURU.Markets; 0.00 serves as the current parameter value. The business relies on global supplies of reagents for diabetes diagnostics. Resilience is ensured by the installed instrument base and asset optimization, which protects the company's current margins.

Trinity Biotech Corp - TRIB Company Debts (period 07/04/2022 - 10/27/2026)

Metric breakdowns and analytics for Trinity Biotech plc (TRIB)

- price and consensus price forecast:

Market Price trinitybiotech.com|TRIB - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Trinity Biotech Corp|TRIB - Enterprise Value

- book capitalization data:

Book Value per Share Trinity Biotech|TRIB - Company Book Value|Capitalization to Book Value Ratio trinitybiotech.com|TRIB - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Trinity Biotech plc|TRIB - Long-Term Debt to Equity|Short-Term Debt to Equity trinitybiotech.com|TRIB - Company Total Debt|Debts to Book Value Trinity Biotech Corp

Fundamental company valuation:Trinity Biotech PLC TRIB

This metric is critical when stress-testing business resilience to credit risks and assessing the issuer's solvency. The total volume of borrowed funds, reflected through total liabilities, measures the aggregate debt load, where the downward debt trend for Trinity Biotech plc (TRIB) signifies the release of resources for expansion into the wearable biosensors segment while maintaining a narrow specialization in laboratory diagnostics.

Key competitors